J07BX05 - Respiratory Syncytial Virus Vaccines |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the respiratory syncytial virus vaccines, no porphyrinogenic effects are expected.
Chemical description
Protein subunit vaccine.
Therapeutic characteristics
Indicated for passive protection against lower respiratory tract disease (RSV) in infants from birth through 6 months of age following maternal immunisation during pregnancy, and for active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by RSV. It is administered by intramuscular injections.
Metabolism and pharmacokinetics
Vaccines are not metabolized by the cytochrome P450 system.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | European Medicines Agency (EMA). SmPC Ixchiq.
|
|
| 2. | Norwegian institute of public health. Vaccines and vaccination.
|
|
Tradenames
Abrysvo · Arexvy · mRESVIA mRNA-vaccin tegen het respiratoir syncytieel virus 
Abrysvo · Arexvy · Mresvia 
Abrysvo · Arexvy · Mresvia 
Abrysvo · mRESVIA 
Abrysvo 
Arexvy 
Abrysvo vaccine 
Abrysvo · Arexvy 
Abrysvo · Arexvy 
Arexvy · mRESVIA 
Abrysvo · Arexvy 
Abrysvo · mRESVIA 
Abrysvo · Arexvy · mRESVIA 
Abrysvo · Arexvy · mRESVIA 
Abrysvo · mRESVIA 
Abrysvo · Arexvy · Mresvia 
Abrysvo 
Abrysvo 
Vaccines